Literature DB >> 12793984

The kallikrein-kinin and the renin-angiotensin systems have a multilayered interaction.

Alvin H Schmaier1.   

Abstract

Understanding the physiological role of the plasma kallikrein-kinin system (KKS) has been hampered by not knowing how the proteins of this proteolytic system, when assembled in the intravascular compartment, become activated under physiological conditions. Recent studies indicate that the enzyme prolylcarboxypeptidase, an ANG II inactivating enzyme, is a prekallikrein activator. The ability of prolylcarboxypeptidase to act in the KKS and the renin-angiotensin system (RAS) indicates a novel interaction between these two systems. This interaction, along with the roles of angiotensin converting enzyme, cross talk between bradykinin and angiotensin-(1-7) action, and the opposite effects of activation of the ANG II receptors 1 and 2 support a hypothesis that the plasma KKS counterbalances the RAS. This review examines the interaction and cross talk between these two protein systems. This analysis suggests that there is a multilayered interaction between these two systems that are important for a wide array of physiological functions.

Entities:  

Mesh:

Year:  2003        PMID: 12793984     DOI: 10.1152/ajpregu.00535.2002

Source DB:  PubMed          Journal:  Am J Physiol Regul Integr Comp Physiol        ISSN: 0363-6119            Impact factor:   3.619


  44 in total

Review 1.  Immunological mechanisms in the pathogenesis of diabetic retinopathy.

Authors:  Anthony P Adamis; Adrienne J Berman
Journal:  Semin Immunopathol       Date:  2008-03-14       Impact factor: 9.623

2.  Physiologic activities of the contact activation system.

Authors:  Alvin H Schmaier
Journal:  Thromb Res       Date:  2014-05       Impact factor: 3.944

3.  The renin-angiotensin system and prolylcarboxypeptidase.

Authors:  Friedrich C Luft
Journal:  J Mol Med (Berl)       Date:  2017-05       Impact factor: 4.599

4.  Role of ACE I/D gene polymorphisms on the effect of ramipril in inflammatory response and myocardial injury in patients undergoing coronary artery bypass grafts.

Authors:  Meral Urhan Küçük; Nehir Sucu; Seyhan Şahan Firat; Barlas Naim Aytaçoğlu; Özden Vezir; Caner Bozali; Necmiye Canacankatan; Seval Kul; Bahar Tunçtan
Journal:  Eur J Clin Pharmacol       Date:  2014-09-27       Impact factor: 2.953

5.  Loss of angiotensin-converting enzyme-2 exacerbates diabetic cardiovascular complications and leads to systolic and vascular dysfunction: a critical role of the angiotensin II/AT1 receptor axis.

Authors:  Vaibhav B Patel; Sreedhar Bodiga; Ratnadeep Basu; Subhash K Das; Wang Wang; Zuocheng Wang; Jennifer Lo; Maria B Grant; JiuChang Zhong; Zamaneh Kassiri; Gavin Y Oudit
Journal:  Circ Res       Date:  2012-04-03       Impact factor: 17.367

6.  Angiotensin-(1-7) administration reduces oxidative stress in diabetic bone marrow.

Authors:  N M Mordwinkin; C J Meeks; S S Jadhav; T Espinoza; N Roda; G S diZerega; S G Louie; K E Rodgers
Journal:  Endocrinology       Date:  2012-03-20       Impact factor: 4.736

7.  Kallikrein activates bradykinin B2 receptors in absence of kininogen.

Authors:  Dauren Biyashev; Fulong Tan; Zhenlong Chen; Kai Zhang; Peter A Deddish; Ervin G Erdös; Claudie Hecquet
Journal:  Am J Physiol Heart Circ Physiol       Date:  2005-11-04       Impact factor: 4.733

Review 8.  Plasma contact factors as therapeutic targets.

Authors:  Benjamin F Tillman; Andras Gruber; Owen J T McCarty; David Gailani
Journal:  Blood Rev       Date:  2018-04-12       Impact factor: 8.250

9.  Reduced levels of neurotransmitter-degrading enzyme PRCP promote a lean phenotype. [corrected].

Authors:  Richard D Palmiter
Journal:  J Clin Invest       Date:  2009-07-20       Impact factor: 14.808

10.  The lupus-susceptibility gene kallikrein downmodulates antibody-mediated glomerulonephritis.

Authors:  Q-Z Li; J Zhou; R Yang; M Yan; Q Ye; K Liu; S Liu; X Shao; L Li; X-J Zhou; E K Wakeland; C Mohan
Journal:  Genes Immun       Date:  2009-03-05       Impact factor: 2.676

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.